× COVID-19 Vaccine Updates: View the latest information.

Call Us 866.600.CARE


Dry Eye and Ocular GVHD Clinic

Dry Eye Disease (DED) is a significant public health problem. At least 14% of the U.S. population more than 50 years old have dry eyes. Chronic ocular graft-versus-host-disease (oGVHD) is an important complication of allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Signs and symptoms of oGVHD mimic other immunologically mediated dry eye diseases (e.g., Sjogren syndrome) without effective treatment regimens available to date. The incidence of oGVHD after bone marrow transplant ranges from 38 to 50%.

In the Dry Eye and ocular GVHD Clinic, we use state-of-the-art diagnostic equipment to assess the severity and type of dry eye. We use customized treatments to treat dry eye and ocular GVHD. We have established a unique translational research program that makes feasible the discovery and development of novel treatments for Dry Eye and ocular GVHD. This program is comprised of a highly specialized ocular GVHD clinic for patient care, an advanced translational molecular biology laboratory for uncovering disease mechanisms, a dedicated clinical trial center for developing new therapies, and a highly motivated team who seamlessly connects these components. The clinical practice and basic laboratory research are highly integrated around the focus area of dry eye and ocular GVHD, which has allowed us to investigate the biological basis of clinical observations in dry eye and ocular GVHD.

To request an appointment, please call 312.996.EYES (3937)


Your Eyes and Chronic GVHD

Watch Dr. Sandeep Jain's presentation at the GVHD patient summit about Chronic Graft-versus-Host Disease in the eyes. In this presentation, Dr. Jain answers questions such as: What is ocular GVHD? Do I have eye GVHD? Is it just another form of dry eye disease? How do you treat ocular GVHD? Will I go blind from it? Do I have to use eye drops forever? Are there any new treatments that can help me? Read the related article, "Living with Chronic GVHD of the Eyes"


Featured Provider Sandeep Jain

Dr. Sandeep Jain is a NIH-funded physician-scientist. He directs the Dry Eye & Ocular GVHD Clinic, Basic Science Laboratory, and Dry Eye Translational Clinic. Dr. Jain is a member of the International Chronic Ocular Graft-vs-Host-Disease Consensus Group and an invited member of the International Dry Eye WorkShop (DEWS). Dr. Jain’s exemplary academic, scientific and entrepreneurial achievements have been formally recognized by the University of Illinois at Chicago (UIC) with numerous awards. He has received ‘Inventor of the Year Award’ at UIC. In the past, Dr. Jain has received the ‘Departmental Faculty of the Year Award’ for his outstanding achievements and faculty contributions to the advancement of vision science. He was also awarded the Physician Scientist award from Research to Prevent Blindness and Achievement award from the American Academy of Ophthalmology.

UIC News Items Highlighting Dr. Jain's Work:

  • UIC researcher awarded $10.15M to develop antibody-based dry eye treatment
  • Immunotherapy for Dry Eye
  • Enzyme-Based Treatment for Dry Eye
  • Inventor of the Year Award
  • Start-Ups Launched from UIC Research 

View Dr. Jain’s Academic Profile


In the Dry Eye and ocular GVHD Clinic, we use state-of-the-art diagnostic equipment to assess the severity and type of dry eye. These include: 

We use customized treatments to treat dry eye and ocular GVHD.  In addition to standard treatments, these include:


Ongoing Clinical Trials and Studies in Dry Eye and ocular GVHD

These clinical trials are funded by a National Institute of Health grant awarded to Dr. Sandeep Jain (NEIR24EY032440)

  • A Phase I/II Randomized Placebo-Controlled, Double-Blind, Single-Center, Tolerability and Preliminary Efficacy Clinical Trial of Intravenous Immunoglobulin (IVIG) Eye Drops In Patients with Dry Eye Disease:
    Protocol #2019-0263
  • Biological Basis of Inflammation in Dry Eye Disease (DED)
    Protocol #2020-0083
  • To investigate whether OSIG therapeutic targets (ACPAs and NETs) cause ocular surface disease directly or through an intermediary (inflammation) and to determine DED clinical features (signs, symptoms or biomarkers) that are significantly associated with OSIG targets (Aim C)
    Protocol #2020-1436
  • Sleep Study of Dry Eye Disease (DED)
    Protocol #2020-0085
  • Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA)
    Protocol #2021-1233
  • Retrospective Chart Review of Patients with Dry Eye Disease or Suspected Dry Eye Disease
    Protocol #2020-0690

Dry Eye and ocular GVHD Clinic Medical Team:

Dry Eye and ocular GVHD Clinic Surgical Team:

Multidisciplinary Collaborators:

Location:

Illinois Eye and Ear
1855 W. Taylor Street
Chicago, IL 60612